MIMETAS

📍 Oegstgeest, Netherlands🗓 Founded 2013👥 118 employees💰 Last funded Apr 2022
Biotechnology Research🌐 mimetas.com
Website LinkedIn
We are a global leader in human 3D disease modeling using our organ-on-a-chip platform, the OrganoPlate®. We work with top pharmaceutical and biotech companies to develop novel therapies against unsolved diseases. Our human tissue & disease modeling expertise and capabilities, robust assays, and high-throughput screening possibilities forms the core of our contribution. Our offering varies from long-term drug discovery partnerships, (custom) model & assay development services compound screening, to off-the-shelf products. For more information, visit: www.mimetas.com.
3
Total investors
0
Early stage
2
Mid stage
1
Late stage
2013
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Netherlands
2
Belgium
1
Investor activity2018–2022 · investors recorded per year
2018220221
Recent (last 2y)Earlier
Frequently asked questions
Who invested in MIMETAS?
MIMETAS has 3 investors on record on gritt.io, 2 mid-stage and 1 late-stage investors.
When did MIMETAS last raise funding?
The most recent investment in MIMETAS recorded on gritt.io was in April 2022.
When was MIMETAS founded?
MIMETAS was founded in 2013.
What industry is MIMETAS in?
MIMETAS operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is MIMETAS based?
MIMETAS is headquartered in Oegstgeest, Netherlands.